First Trust Nasdaq Pharmaceuticals ETF (FTXH)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
First Trust Nasdaq Pharmaceuticals ETF (FTXH) with AI Score 47/100 (Weak). First Trust Nasdaq Pharmaceuticals ETF (FTXH) aims to replicate the performance of the Nasdaq US Smart Pharmaceuticals Index. The fund invests primarily in U. S. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026First Trust Nasdaq Pharmaceuticals ETF (FTXH) Healthcare & Pipeline Overview
First Trust Nasdaq Pharmaceuticals ETF (FTXH) provides focused exposure to the U.S. pharmaceutical sector by mirroring the Nasdaq US Smart Pharmaceuticals Index. The ETF selects holdings based on liquidity and ranking, offering a non-diversified investment vehicle for those seeking to capitalize on the pharmaceutical industry's performance.
Investment Thesis
FTXH offers a focused investment in the U.S. pharmaceutical sector, appealing to investors seeking targeted exposure. The fund's performance is directly tied to the Nasdaq US Smart Pharmaceuticals Index, making it susceptible to sector-specific risks and opportunities. A key consideration is the non-diversified nature of the fund, which amplifies both potential gains and losses. Investors should monitor regulatory changes, drug pricing pressures, and innovation within the pharmaceutical industry, as these factors can significantly impact the fund's performance. The beta of 1.00 indicates that the fund's volatility is similar to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- FTXH aims to replicate the Nasdaq US Smart Pharmaceuticals Index, providing targeted exposure to the U.S. pharmaceutical sector.
- The fund invests at least 90% of its net assets in securities that comprise the index.
- Holdings are selected based on liquidity and ranking within the pharmaceutical sector.
- FTXH operates as a non-diversified fund, concentrating its investments.
- The fund's beta of 1.00 suggests market-average volatility.
Competitors & Peers
Strengths
- Targeted exposure to the U.S. pharmaceutical sector.
- Index-tracking methodology provides transparency.
- Liquidity of holdings allows for easy trading.
- Established brand name of First Trust.
Weaknesses
- Non-diversified nature increases risk.
- Performance is highly dependent on the pharmaceutical sector.
- Subject to regulatory and drug pricing pressures.
- Limited exposure to international pharmaceutical markets.
Catalysts
- Upcoming: Regulatory approvals for new drugs within the index holdings.
- Ongoing: Innovation in pharmaceutical research and development.
- Ongoing: Demographic trends driving increased demand for pharmaceuticals.
Risks
- Potential: Regulatory changes impacting drug pricing and approvals.
- Potential: Patent expirations leading to generic competition.
- Ongoing: Market volatility affecting the pharmaceutical sector.
- Ongoing: Non-diversified nature of the fund amplifying sector-specific risks.
Growth Opportunities
- Innovation in Drug Development: The pharmaceutical industry is driven by constant innovation in drug development, particularly in areas like gene therapy, personalized medicine, and novel drug delivery systems. As companies within the Nasdaq US Smart Pharmaceuticals Index develop and commercialize new drugs, FTXH stands to benefit from the potential revenue growth and market expansion. The global pharmaceuticals market is projected to reach $1.7 trillion by 2027, presenting significant opportunities for growth within the sector.
- Aging Population and Increased Healthcare Spending: The global population is aging, leading to an increased demand for pharmaceutical products and healthcare services. As the elderly population grows, the prevalence of chronic diseases such as diabetes, heart disease, and Alzheimer's also increases, driving demand for pharmaceutical interventions. This demographic trend is expected to continue, providing a long-term growth opportunity for the pharmaceutical industry and, consequently, for FTXH.
- Expansion into Emerging Markets: Emerging markets such as China, India, and Brazil represent significant growth opportunities for the pharmaceutical industry. These markets have large populations, increasing healthcare awareness, and rising disposable incomes, leading to greater demand for pharmaceutical products. As companies within the Nasdaq US Smart Pharmaceuticals Index expand their presence in these emerging markets, FTXH can benefit from the increased revenue and market share.
- Advancements in Biotechnology: Advancements in biotechnology, such as gene editing, CRISPR technology, and immunotherapy, are revolutionizing the pharmaceutical industry. These technologies are enabling the development of new and more effective treatments for a wide range of diseases. As companies within the Nasdaq US Smart Pharmaceuticals Index leverage these advancements to develop innovative therapies, FTXH can benefit from the potential for higher returns and market leadership.
- Regulatory Approvals and Market Exclusivity: The pharmaceutical industry relies heavily on regulatory approvals for new drugs and therapies. When companies within the Nasdaq US Smart Pharmaceuticals Index receive regulatory approvals for their products, they gain market exclusivity for a certain period, allowing them to generate significant revenue and profits. These periods of market exclusivity can be a major driver of growth for pharmaceutical companies and can positively impact the performance of FTXH.
Opportunities
- Growth in the pharmaceutical industry due to aging population.
- Innovation in drug development and biotechnology.
- Expansion into emerging markets.
- Potential for higher returns during periods of strong pharmaceutical sector performance.
Threats
- Regulatory changes and drug pricing pressures.
- Patent expirations and generic competition.
- Economic downturns and reduced healthcare spending.
- Competition from other sector-specific ETFs.
Competitive Advantages
- Established index-tracking methodology.
- Access to a portfolio of leading U.S. pharmaceutical companies.
- Brand recognition and reputation of First Trust.
- Efficient expense ratio for targeted sector exposure.
About FTXH
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is designed to track the performance of the Nasdaq US Smart Pharmaceuticals Index. Launched with the goal of providing investors with targeted exposure to the U.S. pharmaceutical sector, the fund invests at least 90% of its net assets in the securities that comprise the index. The index itself is composed of U.S. companies within the pharmaceutical industry, chosen based on specific criteria including liquidity and overall ranking. FTXH operates as a non-diversified fund, meaning it concentrates its investments in a smaller number of holdings compared to diversified funds. This approach can lead to potentially higher returns but also carries increased risk. The fund's investment strategy focuses on mirroring the index, which is rebalanced periodically to reflect changes in the pharmaceutical market. By tracking the Nasdaq US Smart Pharmaceuticals Index, FTXH aims to provide investors with a convenient and efficient way to participate in the growth and performance of the U.S. pharmaceutical sector.
What They Do
- Tracks the performance of the Nasdaq US Smart Pharmaceuticals Index.
- Invests primarily in U.S. pharmaceutical companies.
- Selects holdings based on liquidity and ranking.
- Provides targeted exposure to the pharmaceutical sector.
- Operates as a non-diversified fund.
- Rebalances its portfolio periodically to reflect index changes.
Business Model
- Replicates the Nasdaq US Smart Pharmaceuticals Index.
- Generates returns based on the performance of its holdings.
- Earns management fees from investors.
- Reinvests dividends received from portfolio companies.
Industry Context
FTXH operates within the broader pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory oversight, and patent protection. The industry is driven by innovation in drug development and faces constant pressure regarding drug pricing and healthcare costs. The competitive landscape includes large multinational corporations, as well as smaller biotech firms focused on niche markets. FTXH's performance is closely tied to the overall health and growth of the U.S. pharmaceutical sector, making it sensitive to industry-specific trends and regulatory changes.
Key Customers
- Individual investors seeking exposure to the pharmaceutical sector.
- Institutional investors looking for targeted investment opportunities.
- Financial advisors seeking to diversify client portfolios.
- Retirement funds and pension plans.
Financials
Chart & Info
First Trust Nasdaq Pharmaceuticals ETF (FTXH) stock price: Price data unavailable
Latest News
No recent news available for FTXH.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FTXH.
Price Targets
Wall Street price target analysis for FTXH.
MoonshotScore
What does this score mean?
The MoonshotScore rates FTXH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
FTXH Healthcare Stock FAQ
What does First Trust Nasdaq Pharmaceuticals ETF do?
First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund designed to mirror the performance of the Nasdaq US Smart Pharmaceuticals Index. The fund achieves this by investing at least 90% of its assets in the stocks that make up the index. This provides investors with a targeted way to invest in the U.S. pharmaceutical sector, focusing on companies selected for their liquidity and overall ranking. As a non-diversified fund, FTXH concentrates its holdings, making it more sensitive to the performance of the pharmaceutical industry compared to broader market ETFs.
What do analysts say about FTXH stock?
AI analysis is currently pending for FTXH, therefore, analyst consensus and valuation metrics are unknown. However, the fund's performance is closely tied to the overall health and growth of the U.S. pharmaceutical sector. Investors should monitor industry-specific factors such as regulatory changes, drug pricing pressures, and innovation in drug development. The fund's beta of 1.00 suggests that its volatility is similar to the overall market. Further analysis will be available once the AI analysis is complete.
What are the main risks for FTXH?
The main risks for FTXH stem from its concentration in the U.S. pharmaceutical sector and its non-diversified nature. Regulatory changes, such as drug pricing reforms or stricter approval processes, can significantly impact the profitability of pharmaceutical companies within the index. Patent expirations and the entry of generic competitors can also erode revenue streams. Additionally, market volatility and economic downturns can negatively affect the pharmaceutical sector, leading to potential losses for FTXH investors. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for FTXH?
First Trust Nasdaq Pharmaceuticals ETF (FTXH) currently holds an AI score of 47/100, indicating low score. Key strength: Targeted exposure to the U.S. pharmaceutical sector.. Primary risk to monitor: Potential: Regulatory changes impacting drug pricing and approvals.. This is not financial advice.
How frequently does FTXH data refresh on this page?
FTXH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FTXH's recent stock price performance?
Recent price movement in First Trust Nasdaq Pharmaceuticals ETF (FTXH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Targeted exposure to the U.S. pharmaceutical sector.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FTXH overvalued or undervalued right now?
Determining whether First Trust Nasdaq Pharmaceuticals ETF (FTXH) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FTXH?
Before investing in First Trust Nasdaq Pharmaceuticals ETF (FTXH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, limiting the depth of financial insights.
- Competitor data is unavailable, hindering comparative analysis.